6:18 PM
 | 
Apr 22, 2013
 |  BC Extra  |  Clinical News

ViroPharma's VP20621 meets C. difficile endpoint

ViroPharma Inc. (NASDAQ:VPHM) said once-daily VP20621 met the primary endpoint in a Phase II trial to prevent recurrent Clostridium difficile infections (CDI). Specifically, all doses of VP20621...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >